Assessing Madrigal Pharmaceuticals (MDGL) Valuation After New Pfizer Partnership In Metabolic Liver Disease

Simply Wall St.01-16

AdvertisementMadrigal’s new Pfizer partnership puts MASH combinations in focus Madrigal Pharmaceuticals (MDGL) just signed an exclusive global license agreement giving Pfizer rights to ervogastat, a ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603193799?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-01-16 04:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603193799","market":"sg","top_or_hot":-1,"title":"Assessing Madrigal Pharmaceuticals (MDGL) Valuation After New Pfizer Partnership In Metabolic Liver Disease","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementMadrigal’s new Pfizer partnership puts MASH combinations in focus Madrigal Pharmaceuticals (MDGL) just signed an exclusive global license agreement giving Pfizer rights to ervogastat, a ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/assessing-madrigal-pharmaceuticals-mdgl-valuation-after-new\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Madrigal Pharmaceuticals (MDGL) Valuation After New Pfizer Partnership In Metabolic Liver Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Madrigal Pharmaceuticals (MDGL) Valuation After New Pfizer Partnership In Metabolic Liver Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-16 04:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/assessing-madrigal-pharmaceuticals-mdgl-valuation-after-new><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementMadrigal’s new Pfizer partnership puts MASH combinations in focus Madrigal Pharmaceuticals (MDGL) just signed an exclusive global license agreement giving Pfizer rights to ervogastat, a ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/assessing-madrigal-pharmaceuticals-mdgl-valuation-after-new\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999011175.SGD","symbol_name":"Nikko AM Global Dividend Equity Dis SGD-H","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/assessing-madrigal-pharmaceuticals-mdgl-valuation-after-new","article_id":"2603193799","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/assessing-madrigal-pharmaceuticals-mdgl-valuation-after-new","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2603193799","pubTimestamp":1768509760,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Madrigal’s new Pfizer partnership puts MASH combinations in focus\nMadrigal Pharmaceuticals (MDGL) just signed an exclusive global license agreement giving Pfizer rights to ervogastat, a clinical-stage oral DGAT-2 inhibitor. This agreement directly targets future combination approaches in metabolic liver disease.\nThe deal centers on DGAT-2’s role in triglyceride assembly and liver fat storage, an area closely linked to inflammation in MASH. Investors now have a new data point to watch as...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","BK4534":"瑞士信贷持仓","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","BK4139":"生物科技","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0058720904.USD":"联博国际健康护理基金A","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4592":"伊斯兰概念","SG9999001176.USD":"United Global Healthcare Acc USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4550":"红杉资本持仓","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4588":"碎股","BK4568":"美国抗疫概念","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","MDGL":"Madrigal Pharmaceuticals, Inc.","SG9999002232.USD":"Allianz Global High Payout USD","BK4007":"制药","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4581":"高盛持仓","BK4599":"减肥药","PFE":"辉瑞","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4585":"ETF&股票定投概念"},"translate_title":"辉瑞在代谢性肝病领域建立新合作伙伴关系后评估Madrigal Pharmaceuticals(MDGL)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDGL":1.5,"PFE":1.5},"content_text":"AdvertisementMadrigal’s new Pfizer partnership puts MASH combinations in focus Madrigal Pharmaceuticals (MDGL) just signed an exclusive global license agreement giving Pfizer rights to ervogastat, a clinical-stage oral DGAT-2 inhibitor. This agreement directly targets future combination approaches in metabolic liver disease. The deal centers on DGAT-2’s role in triglyceride assembly and liver fat storage, an area closely linked to inflammation in MASH. Investors now have a new data point to watch as Madrigal prepares to discuss the agreement at the J.P. Morgan Healthcare Conference on January 12, 2026. See our latest analysis for Madrigal Pharmaceuticals. The Pfizer agreement lands after a volatile stretch, with the latest share price at $505.23 and a 1 day share price return of 2.29% contrasting with a 30 day share price return decline of 9.87%. The 1 year total shareholder return of 84.11% suggests strong longer term momentum. If partnerships in MASH are on your radar, it could be a useful moment to scan other healthcare stocks that might be seeing similar interest and pipeline activity. With Madrigal trading at $505.23, below the average analyst price target and following a mixed run in recent months, is this partnership-driven story underappreciated, or is the market already factoring in future growth? Most Popular Narrative: 16.3% Undervalued With Madrigal shares at $505.23 versus a narrative fair value of about $603.47, the most followed view frames the current price as leaving some upside on the table. The rapid uptake and long-term patent protection of Rezdiffra, supported by a new U.S. patent that extends exclusivity to 2045, provides decades of protected revenue opportunity; this increases the likelihood of sustained top-line growth and supports margin expansion due to extended pricing power. Read the complete narrative. Curious what kind of revenue ramp, margin shift, and future P/E multiple are baked into that fair value? The narrative leans on bold growth, richer profitability, and a premium earnings multiple that outpaces today’s sector yardsticks. The full breakdown shows exactly how those threads are pulled together. Result: Fair Value of $603.47 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this upbeat story can wobble if GLP 1 competitors cap Rezdiffra’s share in earlier stage MASH or if reimbursement hurdles keep pricing and access under pressure. Find out about the key risks to this Madrigal Pharmaceuticals narrative.  Build Your Own Madrigal Pharmaceuticals Narrative If you see the story differently or want to stress test the assumptions yourself, you can build your own view in just a few minutes: Do it your way. A great starting point for your Madrigal Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision. Looking for more investment ideas? If you only stick with one stock, you risk missing other opportunities that fit your style, so broaden your search and stress test your thinking across sectors.  Spot potential value setups by scanning these 875 undervalued stocks based on cash flows where prices and underlying cash flows do not always line up. Lean into long term trends by reviewing these 24 AI penny stocks that are tied to AI adoption across multiple industries. Add some calculated offense by checking out these 80 cryptocurrency and blockchain stocks tied to blockchain, payments, and digital asset infrastructure.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603193799","isCrawlerRequest":true}